13. 多発性硬化症／視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

159 trials found

diseases per page:

Showing 1 to 10 of 159 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05701423 (ClinicalTrials.gov)	February 8, 2023	18/1/2023	A Study of End of Dose Phenomena in Subcutaneous NatalizumabTreated Multiple Sclerosis (MS) Particip ...	End of Dose Phenomena in Subcutaneous Natalizumab Treated MS Patients	Multiple Sclerosis	Drug: Natalizumab	Biogen	NULL	Recruiting	18 Years	N/A	All	100		Germany
2	NCT05418010 (ClinicalTrials.gov)	December 1, 2022	17/2/2022	Natalizumabfor the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclero ...	AttackMS: Natalizumabfor the Treatment of People With Inflammatory Demyelination Suggestive of Multi ...	Multiple Sclerosis;Clinically Isolated Syndrome of Demyelination	Drug: Tysabri Injectable Product;Drug: Placebo	Queen Mary University of London	Biogen;UCL Queen Square Institute of Neurology;Moorfields Eye Hospital NHS Foundation Trust;Barts & ...	Recruiting	18 Years	45 Years	All	40	Phase 2	United Kingdom
3	NCT05532163 (ClinicalTrials.gov)	November 1, 2022	5/9/2022	A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous ...	A Prospective, Multicenter, Interventional, Open-Label, Single-arm Phase IV Study Over 24 Weeks to I ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Natalizumab	Biogen	NULL	Not yet recruiting	18 Years	60 Years	All	40	Phase 4	NULL
4	NCT05177718 (ClinicalTrials.gov)	September 16, 2022	13/12/2021	Natalizumab and Chronic Inflammation	Assessing the Effect of Natalizumabof Magnetic Resonance Imaging Measures of Blood Brain Barrier Per ...	Multiple Sclerosis	Drug: Natalizumab 300 MG in 15 ML Injection	Vanderbilt University Medical Center	Biogen	Recruiting	18 Years	65 Years	All	36	Phase 4	United States
5	JPRN-jRCT2051210146	24/05/2022	26/12/2021	Phase 3 Study to Evaluate Efficacy, Safety, PK, and PD of SC Natalizumabin Japanese Participants Wit ...	A Single-Arm, Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Phar ...	Relapsing-Remitting Multiple Sclerosis	Participants will receive natalizumab 300 mg SC Q4W for 48 weeks.	Amir Hadi Maghzi	NULL	Recruiting	>= 18age old	<= 65age old	Both	20	Phase 3	Japan
6	NCT05304520 (ClinicalTrials.gov)	October 12, 2021	22/3/2022	A Study for Tysabri Participant Preference	SISTER - Subcutaneous: Non-Interventional Study for Tysabri Patient Preference - Experience From Rea ...	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: Natalizumab	Biogen	NULL	Recruiting	18 Years	N/A	All	500		Germany
7	NCT05688436 (ClinicalTrials.gov)	September 24, 2021	9/1/2023	A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate	Pregnancy Outcomes in Women Exposed to Diroximel Fumarate	Multiple Sclerosis	Drug: Diroximel Fumarate;Biological: Alemtuzumab;Drug: Fingolimod;Drug: Glatiramer acetate;Biological ...	Biogen	NULL	Recruiting	18 Years	49 Years	Female	825		United States
8	NCT04964700 (ClinicalTrials.gov)	May 6, 2021	27/5/2021	Analysis of MS Patients Who Have Had Greater Than 60 Infusions of Natalizumab	Analysis of Multiple Sclerosis Patients Who Have Had Greater Than 60 Infusions of Natalizumab: Safet ...	Multiple Sclerosis	Drug: Natalizumab	Multiple Sclerosis Center of Northeastern New York	NULL	Active, not recruiting	18 Years	N/A	All	42		United States
9	NCT04580381 (ClinicalTrials.gov)	September 1, 2020	2/10/2020	Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort	Real World Effectiveness of NatalizumabExtended Interval Dosing in Relapsing-Remitting Multiple Scle ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Natalizumab Injection [Tysabri]	University Hospital, Caen	Biogen	Completed	18 Years	N/A	All	500		France
10	EUCTR2019-003127-38-NL (EUCTR)	09/04/2020	09/04/2020	Research on the effect of add-on high dosage simvastatin treatment on progression in MS patients tre ...	Efficacy of add-on high dose simvastatin on markers for disease progression in MS patients treated w ...	Multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Simvastatin INN or Proposed INN: SIMVASTATIN Other descriptive name: Simvastatine	VUmc Neurology Department	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	100	Phase 2	Netherlands

First Previous1 2 3 4 5…16Next Last